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Pulmonary veno-occlusive disease (PVOD) is rare condition which can lead to severe pulmonary hy-
pertension, right ventricular dysfunction, and cardiopulmonary failure. The diagnosis of PVOD can be
challenging due to its nonspeciﬁc symptoms and its similarity to idiopathic pulmonary arterial hyper-
tension and interstitial lung disease in terms of diagnostic ﬁndings. This case describes a 57 year old
female patient who presented with a 5-month history of progressive dyspnea on exertion and
nonproductive cough. Workup at another hospital was nonspeciﬁc and the patient underwent surgical
lung biopsy due to concern for interstitial lung disease. She subsequently became hemodynamically
unstable and was transferred to our hospital where she presented with severe hypoxemia, hypotension,
and suprasystemic pulmonary artery pressures. Preliminary lung biopsy results suggested idiopathic
pulmonary arterial hypertension and the patient was started on vasodilating agents, including contin-
uous epoprostenol infusion. Pulmonary artery pressures decreased but remained suprasystemic and the
patient did not improve. Final review of the biopsy by a specialized laboratory revealed a diagnosis of
PVOD after which vasodilating therapy was immediately weaned off. Evaluation for dual heart-lung
transplantation was begun. The patient's hospital course was complicated by hypotension requiring
vasopressors, worsening right ventricular dysfunction, and acute kidney injury. During the trans-
plantation evaluation, the patient decided that she did not want to undergo continued attempts at
stabilization of her progressive multi-organ dysfunction and she was transitioned to comfort care. She
expired hours after removing inotropic support.
© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Pulmonary veno-occlusive disease (PVOD) is a rare cause of
pulmonary arterial hypertension (PAH) in which the pulmonary
venules and small veins undergo intimal ﬁbrosis, leading to pul-
monary hypertension, interstitial and pleural edema, and right
ventricular failure [1]. PVOD has been associated with connective
tissue diseases, HIV infection, bone marrow transplantation, andy).
n open access article under the Cchemical exposures but is idiopathic in the majority of cases [2].
Deﬁnitive diagnosis requires lung biopsy for histology but
acquiring such a tissue specimen is usually contraindicated in pa-
tients with respiratory and hemodynamic instability [3]. Although
there are alternative diagnostic tests that are less invasive than
biopsy, without histology it can be difﬁcult to differentiate PVOD
from idiopathic PAH and interstitial lung disease (ILD) [4]. Treat-
ments for PVOD reported in the literature have included PAH-
speciﬁc therapies, which are associated with an increased risk of
pulmonary edema, but which may act as a bridge to lung or com-
bined lung-heart transplantation [5].C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A 57-year-old female presented with a 5-month history of
progressively worsening dyspnea and non-productive cough. Her
symptoms were initially associated only with moderate exertion,
but progressed to dyspnea at rest. Her medical history was signif-
icant for hypertension for which she had been taking a combination
angiotensin receptor blocker-thiazide diuretic for 20 years; she was
a lifetime non-smoker and had no other signiﬁcant history of
cardio-pulmonary disease. Her past surgical, family, and social
history were otherwise non-contributory. On presentation, she was
severely hypoxemic and hypotensive. Cardiac exam revealed a loud
second heart sound, ventricular gallop (S3), parasternal heave, and
tachycardia. Pulmonary examwas signiﬁcant for increased work of
breathing and bilateral rhonchi. Her extremities showed signiﬁcant
bilateral pitting edema up to her thighs. The remainder of her exam
was unremarkable.
Four months prior to admission, the patient had a transthoracic
echocardiogram suggestive of mild-moderate pulmonary hyper-
tension with pulmonary arterial (PA) systolic pressure of approxi-
mately 40 mmHg as well as evidence of septal ﬂattening.
Subsequent left and right-heart catheterization revealed a PA
pressure of 50/19 (mean 31) and non-obstructive coronary artery
disease. Despite aggressive diuresis with furosemide and vasodi-
lator therapy with sildenaﬁl, the patient continued to have wors-
ening dyspnea with associated palpitations.
Prior to admission to our hospital, she underwent an extensive
pulmonary hypertension workup that revealed worsening PA sys-
tolic pressure of approximately 80 mmHg, increased septal ﬂat-
tening with D-shaped left ventricle, and moderate right ventricularFig. 1. Lung biopsy pathology slides. Subpleural vein in intralobular septudilatation. After diuresis, computed tomographic angiography
(CTA) of the chest showed nonspeciﬁc mild reticular interstitial
changes concerning for ILD with no evidence of pulmonary em-
bolism. Pulmonary function tests were signiﬁcant for a diffusing
capacity of the lungs for carbon monoxide at 41% of the predicted
value. Laboratory testing including thyroid function, HIV, and ANA
was unremarkable.
At this point, given the concern for ILD as suggested by the
patient's severe hypoxemia, CTA, and pulmonary function tests, a
decision was made at the outside hospital to perform a bronchos-
copy and video-assisted thoracoscopic lung biopsy, a course of ac-
tion which we would not have recommended. The procedure was
complicated by pulseless electrical activity arrest immediately after
anesthesia induction. The patient underwent cardiopulmonary
resuscitation for less than 5 minutes at which point return of
spontaneous circulation was attained and the procedure was
completed. Subsequently, the patient became hypotensive and
required inotropic support with dopamine and milrinone. Pre-
liminary lung biopsy results were consistent with idiopathic PAH
(IPAH); biopsy slides were sent to a specialized outside laboratory
(Fig. 1). The patient was then transferred to a nearby hospital for
consultation and therapy. She had a Swan-Ganz catheter placed
showing suprasystemic PA pressure of 104/46 (mean 67) mm/Hg;
pulmonary capillary wedge pressure was 10 mmHg with an
augmented cardiac output of 4.98 L/min. The patient was started on
treatment for IPAH including vasodilationwith inhaled nitric oxide,
sildenaﬁl, and epoprostenol. The patient had mild improvement in
her PA pressure but remained hypoxemic and symptomatically
dyspneic.
Two days after initiation of vasodilating agents, ﬁnal review ofm with luminal compromise by proliferating ﬁbrous tissue (arrows).
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weaned off given the risk of iatrogenic pulmonary edema with PA
vasodilation in the setting of PVOD. The patient then underwent
evaluation for a dual heart-lung transplant given her persistent
symptoms and severe hypoxemia with suprasystemic PA pressures.
During the course of this evaluation, the patient decided that she
did not want to undergo the continued attempts at stabilization of
her progressive multi-organ dysfunction as it was not within her
maximal tolerable burden of therapy. The patient was transitioned
to comfort care and expired a few hours after removing her
inotropic support.3. Discussion
PVOD is a rare cause of pulmonary hypertension that is usually
diagnosed late in the disease course and has a very poor prognosis.
The annual incidence of PVOD is estimated at 0.1 to 0.2 cases per
million persons with many cases misdiagnosed as other etiologies
of IPAH [6]. Most cases of PVOD are idiopathic but the disease has
also been reported in association with connective tissue diseases,
HIV infection, bone marrow transplant, and exposure to ano-
rexigens and some chemotherapeutic agents [2]. Histologically, the
predominant lesion is intimal ﬁbrosis occurring most commonly in
small veins. This ﬁbrosis causes obstruction of pulmonary veins,
resulting in pulmonary capillary congestion, interstitial and pleural
edema, lymphadenopathy, and alveolar hemosiderosis [1]. Pulmo-
nary arterial occlusion also occurs in as many as half of patients
with PVOD [7]. Chronically, patients develop PAH, right ventricular
dysfunction, and in spite of medical therapy, progress to cardio-
pulmonary failure.
PVOD can be difﬁcult to diagnose and patients usually progress
to a New York Heart Association functional class III or IV before
histological conﬁrmation [2]. The difﬁculty in diagnosing PVOD is
due to its nonspeciﬁc symptoms and clinical ﬁndingswhich are also
compatible with IPAH, which occurs more commonly than PVOD.Fig. 2. Pulmonary artery systolic pressure, systemic systolic blood pressure, and cardiac
artery pressures remained suprasystemic. Weaning off epoprostenol resulted in increases i
decline.Deﬁnitive diagnosis requires histological examination of lung tissue
but a biopsy is usually contraindicated in patients with advanced
disease and tenuous hemodynamic status. If a biopsy is to be per-
formed, the anesthesiologist should be aware of the diagnosis of
pulmonary hypertension since the risk of right-sided heart failure
is markedly increased. Additionally, optimal pulmonary blood ﬂow
should be maintained throughout the procedure [8]. The patient
described in this report had PEA arrest during bronchoscopy at the
outside hospital. Moreover, the patient was initially diagnosed with
IPAH before a second reading of her lung biopsy slides revealed a
diagnosis of PVOD. This case thus highlights the importance of
conﬁrming preliminary pathology reports and underscores the
risks of invasive procedures in the context of signiﬁcant cardio-
pulmonary disease.
Clinical suspicion must be high in order to diagnose PVOD.
Approximately 10% of patients thought to have IPAH actually have
PVOD [6]. A case series showed that 12 of 14 patients with clinically
diagnosed PAH who failed to respond to medical therapy actually
had PVOD on examination of lung tissue [9]. Guidelines for the
diagnosis and treatment of pulmonary hypertension recommend
noninvasive tests when evaluating a patient for PVOD [3]. With the
exception of a reduced DLCO, pulmonary function tests are usually
within normal limits in patients with PVOD. In patients with pre-
sumed PAH, a DLCO <55% has a sensitivity of 64.3% and speciﬁcity
of 89.5% for a diagnosis of PVOD [10]. High resolution CT often
shows centrilobular ground-class opacities, thickened septal lines,
and mediastinal lymph node enlargement. Bronchoalveolar lavage,
although not required in all patients being evaluated for PAH, may
be performed to detect an increased alveolar cell count with an
elevated percentage of hemosiderin-laden macrophages, a ﬁnding
that favors PVOD over other causes of PAH [2].
A common complication of PAH is right ventricular dysfunction.
On presentation, our patient required vasoactive support which
could not be weaned off. Before PVOD was diagnosed, PAH-speciﬁc
therapies (inhaled nitric oxide, sildenaﬁl, and epoprostenol) wereindex in response to epoprostenol infusion. During epoprostenol infusion, pulmonary
n both pressures but did not improve the patient's cardiac index, which continued to
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patient's pulmonary and systemic pressures both decreased, but
she remained severely hypoxemic and pulmonary pressures
remained suprasystemic. When a second pathology reading
conﬁrmed PVOD as the diagnosis, epoprostenol was weaned off
due to the concern for pulmonary edema in PVOD patients being
treated with vasodilators [2,5]. Discontinuation of epoprostenol
resulted in subsequent increases in systemic and pulmonary
pressures. During this time, progressively increasing pulmonary
artery pressures were associated with a decline in cardiac index
(Fig. 2), likely due to increased right ventricular dysfunction. The
patient's complaint of shortness of breath remained constant dur-
ing hospitalization and she continued to have an extremely high
oxygen requirement.
Our patient also developed acute kidney injury, most likely of
cardiorenal etiology. Clinically, serum creatinine doubled, blood
urea nitrogen (BUN) progressively increased, lower extremity
edema worsened, and the patient became oliguric. Diuresis with
maximum doses of intravenous bumetanide and oral metolazone
resulted in increases in urine output but did not normalize the
creatinine or BUN. Numerous discussions were had between con-
sultants on diuresis goals given the tenuous balance between
maintaining perfusion in the context of a preload-dependent state
and the risk of persistent vascular congestion leading to pulmonary
edema. This case highlights the difﬁculty in managing ﬂuid status
in patients diagnosed with PVOD.
The use of PAH-speciﬁc therapies in treating PVOD requires
close clinical surveillance because of the risk of pulmonary edema
that comes with preferential dilation of pulmonary arteries. The
literature includes a case of PVOD where a patient expired after she
developed acute pulmonary edema and respiratory failure
following initiation of low-dose prostacyclin infusion [11]. More
recently, cautious administration of epoprostenol has been shown
to temporarily improve clinical and hemodynamic parameters in
some patients with PVOD, acting as a bridge to lung transplantation
[5]. Although all classes of PAH-speciﬁc vasodilators are associated
with pulmonary edema in PVOD patients, another report describes
a case with a patient who experienced worsening hypoxemia after
starting low-dose epoprostenol but improved with other vaso-
dilating agents [12]. Similarly, our patient did not tolerate low-dose
epoprostenol as she was hypotensive despite inotropic support.
Had she continued to receive epoprostenol, she might have
decompensated even further. For most of her hospitalization,
however, she was maintained on inhaled nitric oxide and oral sil-
denaﬁl. Although there is evidence that epoprostenol infusion can
be helpful in some PVOD patients, our case and other cases previ-
ously reported suggest that not all patients with PVOD will gainbeneﬁt from prostacyclin therapy.
In conclusion, PVOD is a rare cause of PAH and is usually diag-
nosed late in the course of disease. There is no clearly demonstrated
effective nonsurgical therapy and it is unclear which patients will
beneﬁt from prostacyclin infusion as a bridge to lung trans-
plantation, which is the only effective treatment for PVOD. The
patient in this case experienced hypotension secondary to severe
right ventricular dysfunction and epoprostenol infusion which
resulted in acute kidney injury. When treating patients with PAH, it
is important to make an accurate diagnosis quickly while weighing
the risks and beneﬁts of various diagnostic tests and therapeutic
options. Vasodilator therapy in PVOD, if started, must be done so
cautiously. Finally, management of ﬂuids in patients with cardio-
genic shock and acute kidney injury is difﬁcult and should be done
in consultation with a cardiologist and nephrologist.References
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